Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
EFC17905
Hemophilia Phase III
- 10.4 weeks
- 1st site activated in Canada
EFC18055
Rheumatology Phase IV
- 8.8 weeks
HF-POLARIS (NN9490-8266)
Heart Failure Phase III
- 9.8 weeks
HF-POLARIS (NN9490-8266)
Heart Failure Phase III
- 12 weeks
HF-POLARIS (NN9490-8266)
Heart Failure Phase III
- 9.6 weeks
NN6706-8212
Heart Failure Phase II
- 8.4 weeks
PDY19372
Lung diseases Phase IIa
- 8.2 weeks
WO46069
Breast Cancer Phase II/III
- 9.4 weeks
- 1st site activated in Canada
WO46069
Breast Cancer Phase II/III
- 8.8 weeks
WO46069
Breast Cancer Phase II/III
- 8 weeks
1245-0256
Nephrology (Chronic kidney disease) Phase III
- 9 weeks
- 1st site activated in Canada
1493-0002
Idiopathic Pulmonary Fibrosis Phase IIa
- 15.6 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 6.4 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 8.2 weeks
20230005
Prostate Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada and Canadian FPI
20230222
Elevated Lipoprotein(a) Phase III
- 3.8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8.4 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 11.4 weeks
20240031
Oncology Phase I
- 9.4 weeks